Two Delaware lawmakers who led the push to legalize marijuana are now seeking input from consumers and businesses as the state’s commercial retail market prepares to launch on August 1.

The idea is to identify any hiccups that lawmakers might need to address when they return for next year’s legislative session.

House Majority Whip Rep. Ed Osienski (D)—the primary sponsor of HB 1 and HB 2—and Sen. Trey Paradee (D), who also sponsored the legalization legislation, have put out a new online form for residents to share thoughts and feedback anonymously.

Hosted on a Delaware Senate Democrats website, the input form says that “whether you are a customer or a retailer, we want to hear your experience with Delaware’s adult-use cannabis sale rollout.”

The lawmakers said the aim of the outreach, first reported by Delaware Online, is “so that we may better advocate for any needed policy adjustments in the state legislature when we return in 2026.”

Lawmakers in 2023 passed HB 1 and HB 2 to legalize and regulate adult-use cannabis—bills that then-Gov. John Carney (D) allowed to become law without his signature.

Regulators last month announced that legal cannabis sales to people 21 and older would begin on August 1.

“The start of legal adult-use marijuana sales reflects the tireless efforts of our regulatory team and our strong partnerships with state agencies, industry stakeholders, and community leaders,” Marijuana Commissioner Joshua Sanderlin said in a press release, adding that the state’s focus “is on building a safe, equitable, and accountable marijuana market that delivers real benefits to Delawareans.”

Offering products will be all seven of Delaware’s existing medical marijuana operators, which have since converted to adult-use retailers. There are at least 13 locations across the state expected to be open for recreational sales next month.

Current Gov. Matt Meyer (D) has cheered the development, recently saying that “Delaware has taken a major step forward by launching a legal adult-use cannabis market that prioritizes equity, safety, and accountability.”

“This new industry will generate critical revenue to strengthen our schools, infrastructure, and public health systems, while creating real opportunities for entrepreneurs,” the governor said. “This revenue also gives us a powerful tool to invest in the communities most impacted by the war on drugs, addressing past wrongs and ensuring that the benefits of this new market reach every corner of our state.”

The state’s Office of the Marijuana Commissioner (OCM) initially projected that recreational sales would start by March, but complications related to securing an FBI fingerprint background check service code delayed the implementation. Lawmakers passed a bill in April to resolve the issue, and the FBI subsequently issued the code that the stat’s marijuana law requires.

Late last year, OMC held a series of licensing lotteries for cannabis business to start serving adult consumers.

A total of 125 licenses will ultimately be issued, including 30 retailers, 60 cultivators, 30 manufacturers and five testing labs. Last year, regulators also detailed what portion of each category is reserved for social equity applicants, microbusinesses and general open licenses.

Regulators have also been rolling out a series of proposed regulations to stand up the forthcoming adult-use cannabis industry.

Meanwhile, Carney raised eyebrows in January after making a questionable claim that “nobody” wants cannabis shops in their neighborhoods, even if there’s consensus that criminalization doesn’t work.

The then-governor last year signed several additional marijuana bills into law, including measures that would allow existing medical cannabis businesses in the state to begin recreational sales on an expedited basis, transfer regulatory authority for the medical program and make technical changes to marijuana statutes.

The dual licensing legislation is meant to allow recreational sales to begin months earlier than planned, though critics say the legislation would give an unfair market advantage to larger, more dominant businesses already operating in multiple states.

In October, Carney also gave final approval to legislation to enact state-level protections for banks that provide services to licensed marijuana businesses.

Delaware’s medical marijuana program is also being significantly expanded under a law that officially took effect last July.

The policy change removes limitations for patient eligibility based on a specific set of qualifying health conditions. Instead, doctors will be able to issue cannabis recommendations for any condition they see fit.

The law also allows patients over the age of 65 to self-certify for medical cannabis access without the need for a doctor’s recommendation.

Photo courtesy of Chris Wallis // Side Pocket Images.

It’s 7/10.

Flip it and you get OIL. Simple as that.

Nothing too fancy. Just stoners with rigs and a love for the herb. A number turned sideways, a ritual passed hand to hand.

Long before 710 was a holiday, it was a whisper in online forums. Now it’s something else entirely: a day for the people who never stopped torching.

At High Times, we didn’t just watch this happen. We chronicled it. Pushed it. Got our fingers sticky with it. From the first whispers of BHO to glass tech that looked like it came from another galaxy, we were there.

Today, we look back, not out of nostalgia, but out of respect. Because this history still bubbles. And it still burns.

From the Vault: Covers That Hit Like a Dab

You know these.

Maybe they’re under your bed with a ring of reclaim on the corner. Maybe you ripped one apart to make a rolling tray. Doesn’t matter; they’re part of the culture now.

Every cover on that list came from a time when concentrates were still shaping their voice. And we helped put it on the loudspeaker.

Stories That Made It Real

“All Hail 7/10” – Mary Jane Gibson (2014)

The one that gave the holiday its headline. Witty, weird, and full of lore: Taco Bell stats, freeway signs, and a tip of the hat to Schapelle Corby.

Read it →

“Happy 710! Tidbits and Trivia” (2023)

A quick cruise through the history and meaning of 710. Ancient hash, modern diamonds, angel numbers. Dab day with depth.

Read it →

“Dabbling in Dabs” – Benjamin M. Adams (2023)

A full-spectrum dive. Rosin first surfaced on cannabis forums in the mid-2000s. The science behind shatter. The 710 Cup. Concentrate culture, unraveled.

Read it →

“Generation Dab” – Bobby Black (2013)

Straight from the Cups, when booths were stacked with butane tanks and rigs lit like lighters.

Read it →

“Vaporizing THC Oil” – Dr. Lunglife (1989)

Before “dab” was even a word. This relic shows how far we’ve come, from Bic pens and dimmer switches to high-end rosin presses.

Read it →

“9 Dab Videos You Need to See” (2017)

Fails, flexes, grandma with a gram. A time capsule of chaos. Dab culture caught in pixels.

Read it →

So Why Does 7/10 Still Matter?

Because nobody handed it to us.

It wasn’t a marketing stunt or a wellness campaign. It started in someone’s garage. In a forum post. In a back-of-the-sesh whisper.

Built by extract artists with burned knuckles and cracked lips. By stoners who cared about flavor. About feeling. About refining the plant into gold.

710 is for the ones who stuck around. The ones still here for it.

Lead image by Chewberto420

Former U.S. House Speaker Newt Gingrich (R-GA) says the psychedelic ibogaine represents an “astonishing breakthrough” in the nation’s current “sick care system” that’s left people with serious mental health conditions without access to promising alternative treatment options—and he intends to use his influence to advance the issue.

Gingrich, who has a mixed record on drug policy reform, spoke with W. Brian Hubbard, executive director of Americans for Ibogaine during a podcast interview that was published recently, and he expressed serious interest in promoting access to the psychedelic that’s been used in the treatment of conditions such as post-traumatic stress disorder (PTSD), traumatic brain injury (TBI), substance misuse and more.

The former speaker is adding his voice to a growing, bipartisan choir of voices from current and former officials who see an opportunity with psychedelics to fill the treatment gap in the U.S.—particularly for military veterans.

“This could be an astonishing breakthrough in what has been a long losing struggle with addiction across this country,” Gingrich said. “It strikes me that the whole ‘Make America Healthy Again’ movement—that this could be a very significant building block in getting us back to being a country that’s not addicted. I can’t imagine a more timely podcast than to be talking with you about this.”

“We currently have a sick care system when we need a healthcare system,” he said. “This strikes me as a perfect example of that. This is very, very exciting to me.”

While acknowledging that the Food and Drug Administration (FDA) needs to “balance risk against certainty” and emphasizing the need for studies to support the use of ibogaine in a “controlled environment,” Gingrich said he was “so inspired” by the conversation he had with Hubbard that he’s “personally going to be strongly engaged in moving the idea around and getting people to look at it.”

“You’re really doing something which will, over the next generation, save several million lives. It’s amazing,” the former speaker said.

The message around the therapeutic potential of psychedelics has been getting out in a number of ways, including in prominent conservative media circles and within the Trump administration.

For example, a Navy SEAL veteran credited with killing Osama Bin Laden said during a Fox News interview this week that psychedelic therapy has helped him process the trauma he experienced during his time in the military, stressing that “it works” and should be an available treatment option.

That interview came days after the U.S. House of Representatives included an amendment to a spending bill from Reps. Lou Correa (D-CA) and Jack Bergman (R-MI) that would encourage VA to support research into the benefits of psychedelics in treating medical conditions commonly affecting military veterans.

Last month, meanwhile, U.S. Department of Health and Human Services (HHS) Secretary Robert F. Kennedy Jr. said his agency is “absolutely committed” to expanding research on the benefits of psychedelic therapy and, alongside of the head of FDA, is aiming to provide legal access to such substances for military veterans “within 12 months.”

U.S. Department of Veterans Affairs (VA) Secretary Doug Collins also disclosed in April that he had an “eye-opening” talk with Kennedy about the therapeutic potential of psychedelic medicine. And he said he’s open to the idea of having the government provide vouchers to cover the costs of psychedelic therapy for veterans who receive services outside of VA as Congress considers pathways for access.

Collins also recently visited a facility conducting research on psychedelics, and he reiterated that it’s his “promise” to advance research into the therapeutic potential of the substances—even if that might take certain policy changes within the department and with congressional support.

The secretary’s visit to the psychedelics research center came about a month after the VA secretary met with a military veteran who’s become an advocate for psilocybin access to discuss the therapeutic potential of psychedelic medicine for the veteran community.

Collins also briefly raised the issue in a Cabinet meeting with President Donald Trump in April.

Meanwhile last month, bipartisan congressional lawmakers asked the VA head to meet with them to discuss ways to provide access to psychedelic medicine for military veterans.

In a letter sent to Collins, Reps. Lou Correa (D-CA) and Jack Bergman (R-MI)—co-chairs of the Congressional Psychedelic Advancing Therapies (PATH) Caucus—said they were “encouraged by your recent remarks about the importance of pursuing research into psychedelic treatments and other alternative treatments to improve Veterans’ care.”

Correa and Bergman separately introduced a bill in April to provide $30 million in funding annually to establish psychedelics-focused “centers for excellence” at VA facilities, where veterans could receive novel treatment involving substances like psilocybin, MDMA and ibogaine.

—
Marijuana Moment is tracking hundreds of cannabis, psychedelics and drug policy bills in state legislatures and Congress this year. Patreon supporters pledging at least $25/month get access to our interactive maps, charts and hearing calendar so they don’t miss any developments.

Learn more about our marijuana bill tracker and become a supporter on Patreon to get access.
—

Bergman has also expressed optimism about the prospects of advancing psychedelics reform under Trump, arguing that the administration’s efforts to cut spending and the federal workforce will give agencies “spines” to tackle such complex issues.

Kennedy, for his part, also said in April that he had a “wonderful experience” with LSD at 15 years old, which he took because he thought he’d be able to see dinosaurs, as portrayed in a comic book he was a fan of.

Last October, Kennedy specifically criticized FDA under the prior administration over the agency’s “suppression of psychedelics” and a laundry list of other issues that he said amounted to a “war on public health” that would end under the Trump administration.

In December, VA separately announced that it’s providing $1.5 million in funding to study the efficacy of MDMA-assisted therapy for veterans with PTSD and alcohol use disorder (AUD).

Last year, VA’s Yehuda also touted an initial study the agency funded that produced “stunning and robust results” from its first-ever clinical trial into MDMA therapy.

In January, former VA Under Secretary for Health Shereef Elnahal said that it was “very encouraging” that Trump’s pick to have Kennedy lead HHS has supported psychedelics reform. And he hoped to work with him on the issue if he stayed on for the next administration, but that didn’t pan out.

Photo courtesy of Flickr/Scamperdale.